ATE64530T1 - Verwendung von hyperimmunmilch zur herstellung eines arzneimittels zur behandlung von cardiovaskul|ren krankheiten und zur verringung von blutfettwerten. - Google Patents

Verwendung von hyperimmunmilch zur herstellung eines arzneimittels zur behandlung von cardiovaskul|ren krankheiten und zur verringung von blutfettwerten.

Info

Publication number
ATE64530T1
ATE64530T1 AT84112946T AT84112946T ATE64530T1 AT E64530 T1 ATE64530 T1 AT E64530T1 AT 84112946 T AT84112946 T AT 84112946T AT 84112946 T AT84112946 T AT 84112946T AT E64530 T1 ATE64530 T1 AT E64530T1
Authority
AT
Austria
Prior art keywords
medication
manufacture
treatment
cardiovascular diseases
blood fat
Prior art date
Application number
AT84112946T
Other languages
German (de)
English (en)
Inventor
Ralph J Stolle
Lee R Dr Beck
Original Assignee
Stolle Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stolle Res & Dev filed Critical Stolle Res & Dev
Application granted granted Critical
Publication of ATE64530T1 publication Critical patent/ATE64530T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39508—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from milk, i.e. lactoglobulins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT84112946T 1983-10-27 1984-10-26 Verwendung von hyperimmunmilch zur herstellung eines arzneimittels zur behandlung von cardiovaskul|ren krankheiten und zur verringung von blutfettwerten. ATE64530T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/546,162 US4636384A (en) 1982-06-03 1983-10-27 Method for treating disorders of the vascular and pulmonary systems
EP84112946A EP0143345B1 (en) 1983-10-27 1984-10-26 Use of hyperimmune milk for the manufacture of a medicament for the treatment of cardio-vascular diseases or for lowering lipid bloodstream levels

Publications (1)

Publication Number Publication Date
ATE64530T1 true ATE64530T1 (de) 1991-07-15

Family

ID=24179138

Family Applications (2)

Application Number Title Priority Date Filing Date
AT84112946T ATE64530T1 (de) 1983-10-27 1984-10-26 Verwendung von hyperimmunmilch zur herstellung eines arzneimittels zur behandlung von cardiovaskul|ren krankheiten und zur verringung von blutfettwerten.
AT90101230T ATE100325T1 (de) 1983-10-27 1990-01-22 Verwendung von milch zur herstellung einer hyperimmunmilchverbindung zur behandlung von erkrankungen des atmungssystems bei saeugetieren.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT90101230T ATE100325T1 (de) 1983-10-27 1990-01-22 Verwendung von milch zur herstellung einer hyperimmunmilchverbindung zur behandlung von erkrankungen des atmungssystems bei saeugetieren.

Country Status (7)

Country Link
US (1) US4636384A (enExample)
EP (2) EP0380032B1 (enExample)
AT (2) ATE64530T1 (enExample)
CH (1) CH671517A5 (enExample)
DE (2) DE3448494C2 (enExample)
NL (1) NL8403248A (enExample)
SE (1) SE466532B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849349A (en) * 1982-06-03 1998-12-15 Dcv, Inc. Anti-cholesterolemic egg, vaccine and method for production, and use
US5753268A (en) * 1982-06-03 1998-05-19 Dcv Biologics, L.P. Anti-cholesterolemic egg, vaccine and method for production, and use
US5130128A (en) * 1982-06-03 1992-07-14 Stolle Research & Development Corporation Use of honey as vaccine
US5650175A (en) * 1982-06-03 1997-07-22 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5863561A (en) * 1982-06-03 1999-01-26 Stolle Research & Development Corporation Immune suppressive product
US5352462A (en) * 1982-06-03 1994-10-04 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5853765A (en) * 1982-06-03 1998-12-29 Dcv, Inc. Anti-cholesterolemic egg, vaccine and method for production, and use
US4879110A (en) * 1983-10-27 1989-11-07 Stolle Research And Development Corporation Antihypertensive hyperimmune milk, production, composition, and use
US5242691A (en) * 1982-06-03 1993-09-07 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US4897265A (en) * 1983-10-27 1990-01-30 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US4956349A (en) * 1983-10-27 1990-09-11 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5194255A (en) * 1982-06-03 1993-03-16 Stolle Research & Development Corporation Antihypertensive hyperimmune milk, production, composition, and use
US5215746A (en) * 1982-06-03 1993-06-01 Stolle Research And Development Corporation Anti-cholesterolemic egg, vaccine and method for production, and use
US6054124A (en) * 1982-06-03 2000-04-25 Stolle Milk Biologics, Inc. Immune suppressive product
US4994496A (en) * 1987-09-09 1991-02-19 Repasky Elizabeth A Use of milk globules as carriers for drugs
AU629559B2 (en) * 1988-08-04 1992-10-08 Thomas Julius Borody Oral antibody therapy for patients with lowered immune response and composition therefor
US5128127A (en) * 1989-02-08 1992-07-07 Stolle Research & Development Corp. Increased protein production in animals
JP3054194B2 (ja) * 1990-07-05 2000-06-19 ストール・ミルク・バイオロジクス・インコーポレイテッド 免疫抑制生産物
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
JPH07507798A (ja) * 1992-06-16 1995-08-31 ストール・ミルク・バイオロジクス・インコーポレイテッド 寿命延長のための高度免疫乳の使用
US6056978A (en) * 1992-06-16 2000-05-02 Stolle Milk Biologics, Inc. Use of hyperimmune milk to prevent suppression of T-lymphocyte production
FI955692A7 (fi) * 1993-05-26 1996-01-24 Stolle Res & Development Anti-kolesteroleminen muna, rokote ja valmistusmenetelmä sekä käyttö
US5980953A (en) * 1994-10-03 1999-11-09 Stolle Milk Biologics, Inc. Anti-inflammatory factor, method of isolation, and use
FI955389A0 (fi) * 1995-11-09 1995-11-09 Antti Sakari Aaltonen Tandskyddande profylaktisk preparat och administreringsmedlen emot mellanoerpatogener
US20020161199A1 (en) * 1998-04-08 2002-10-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US5980044A (en) * 1998-09-16 1999-11-09 Evans & Sutherland Computer Corp. Area of interest display system with image combining using error dithering
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
JP2004501199A (ja) * 2000-06-28 2004-01-15 セリカウサ　ベーヴェー 異化乳清から成るまたは少なくとも異化乳清を含む組成物の使用
AU2002309486A1 (en) * 2001-01-30 2002-10-15 The Lauridsen Group, Incorporated Methods and compositions for modulating the immune system of animals
US20030190314A1 (en) * 2001-01-30 2003-10-09 The Lauridsen Group Methods and compositions of treatment for modulating the immune system of animals
PL211753B1 (pl) * 2001-01-30 2012-06-29 Lauridsen Group Zastosowanie koncentratu antygenowo nie-specyficznych immunoglobulin pochodzących z krwi zwierząt i kompozycja farmaceutyczna zawierająca immunoglobuliny
US6770280B1 (en) 2001-11-15 2004-08-03 Humanetics Corporation Treatment of menorrhagia, hypermenorrhea, dysmenorrhea and menstrual migraines by the administration of an antibacterial milk product
US20030223985A1 (en) * 2002-05-29 2003-12-04 The Lauridsen Group. Incorporated Globulin protein to lower cholesterol in humans
US20060013890A1 (en) * 2004-06-24 2006-01-19 Green Shawn J Dairy-derived anticholesterol immunoglobulin to lower dietary cholesterol in humans
US20070087002A1 (en) * 2005-10-14 2007-04-19 Green Shawn J Anticholesterol immunoglobulin to treat lipid raft diseases
US7891818B2 (en) 2006-12-12 2011-02-22 Evans & Sutherland Computer Corporation System and method for aligning RGB light in a single modulator projector
US8358317B2 (en) 2008-05-23 2013-01-22 Evans & Sutherland Computer Corporation System and method for displaying a planar image on a curved surface
US8702248B1 (en) 2008-06-11 2014-04-22 Evans & Sutherland Computer Corporation Projection method for reducing interpixel gaps on a viewing surface
US8077378B1 (en) 2008-11-12 2011-12-13 Evans & Sutherland Computer Corporation Calibration system and method for light modulation device
US9641826B1 (en) 2011-10-06 2017-05-02 Evans & Sutherland Computer Corporation System and method for displaying distant 3-D stereo on a dome surface

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128230A (en) * 1961-04-04 1964-04-07 Sunbury Milk Products Co Milk having antibodies therein and process for producing same
US3376198A (en) * 1965-07-21 1968-04-02 Collins Products Inc Method of producing antibodies in milk
US3911108A (en) * 1973-02-14 1975-10-07 Diamond Shamrock Corp Process of producing bovine milk products containing specific antibodies
US4324782A (en) * 1974-01-28 1982-04-13 Beck Lee R Dental caries inhibiting product of immunized cow's milk having antibodies specific to killed Streptococcus mutans cells
GB1505513A (en) * 1975-05-23 1978-03-30 Stolle Res & Dev Dental caries inhibiting product
SE448344B (sv) * 1978-02-06 1987-02-16 Stolle Res & Dev Antikropp for behandling av reumatoid artrit samt sett att framstella denna
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
US4377569A (en) * 1980-01-21 1983-03-22 Plymate Robert R Method of treating animals to resist infectious diseases
DE3172807D1 (en) * 1981-04-28 1985-12-12 Stolle Res & Dev Method of obtaining an anti-inflammatory bovine milk

Also Published As

Publication number Publication date
EP0380032B1 (en) 1994-01-19
ATE100325T1 (de) 1994-02-15
SE8405351D0 (sv) 1984-10-26
DE3448494C2 (enExample) 1993-09-23
EP0143345A3 (en) 1987-09-30
HK1006004A1 (en) 1999-02-05
EP0143345A2 (en) 1985-06-05
SE8405351L (sv) 1985-04-28
DE3439345A1 (de) 1986-04-24
EP0380032A1 (en) 1990-08-01
US4636384A (en) 1987-01-13
EP0143345B1 (en) 1991-06-19
NL8403248A (nl) 1985-05-17
DE3439345C2 (de) 1993-10-14
CH671517A5 (enExample) 1989-09-15
SE466532B (sv) 1992-03-02

Similar Documents

Publication Publication Date Title
ATE100325T1 (de) Verwendung von milch zur herstellung einer hyperimmunmilchverbindung zur behandlung von erkrankungen des atmungssystems bei saeugetieren.
DE69012591D1 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
Danaraj et al. Primary arteritis of abdominal aorta in children causing bilateral stenosis of renal arteries and hypertension
Carey et al. Homocystinuria: I. A clinical and pathological study of nine subjects in six families
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
DE69533040D1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE144142T1 (de) Verwendung von thiazolidin-4-carboxylatderivaten zur behandlung von lungenerkrankungen
ATE66374T1 (de) Zubereitungen und verfahren zur behandlung von blutungsstoerungen.
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ES2073425T3 (es) Una nueva glicoproteina de tipo trombomodulina susceptible de ser obtenida a partir de la orina.
DE3685853D1 (de) Mittel zur behandlung von knochenkrankheiten.
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69021257D1 (de) Verwendung von IFN-gamma zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von ATL.
DE69915848D1 (de) Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte
Schmiegelow The Surgical Treatment of Chronic Cicatricial Stenosis of the Larynx:(Semon Lecture 1937)
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
Byrne Music therapy and reminiscence: A case study.
Rocchi et al. Effect of vitamin A acetate on mutagenesis induced by ultraviolet light in human cells
Gekler et al. Tuberculous cavitation of the lung: mechanical factors in its genesis, and combined chemotherapeutic and surgical treatment
Kelly Brain from a Patient who presented Nystagmoid Movements in the Pharynx and Larynx
VALTONEN et al. EFFECT OF TIMING AND DURATION OF THE SYNCARDIAL PRESSURE PULSES ON SKIN TEMPERATURE AND I'LETHYSMOGRAM OF THE LEGS
DE3850691D1 (de) Verwendung von Dopamin-Agonisten zur Herstellung eines Arzneimittels für die Behandlung von Knochenverletzungen.
SMITH Spontaneous Gangrene of the Extremities
Pastore et al. 793bis—Interpretation of low-frequency pulsating magnetic field effects on patients affected by peripheral arteriopathy

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee